These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24168807)

  • 1. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials.
    Pae CU; Patkar AA; Jang S; Portland KB; Jung S; Nelson JC
    CNS Spectr; 2014 Aug; 19(4):324-9. PubMed ID: 24168807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
    Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
    J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
    Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
    Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
    Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
    J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD
    J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
    Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD
    J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA; Amsterdam JD
    Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.
    DelBello MP; Hochadel TJ; Portland KB; Azzaro AJ; Katic A; Khan A; Emslie G
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):311-7. PubMed ID: 24955812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS; Amsterdam JD
    J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
    Patkar AA; Pae CU; Masand PS
    CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
    BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC
    Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).
    Nakonezny PA; Mayes TL; Byerly MJ; Emslie GJ
    J Psychiatr Res; 2015 Sep; 68():346-53. PubMed ID: 26028546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    Farabaugh A; Mischoulon D; Fava M; Wu SL; Mascarini A; Tossani E; Alpert JE
    Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial.
    Zhang L; Xie WW; Li LH; Zhang HG; Wang G; Chen DC; Cao Y; Cui LJ; Zhang KR; Shi JG; Tan QR; Zheng HB; Xu XF; Cheng ZH; Zhao JP
    Pharmacology; 2014; 94(5-6):199-206. PubMed ID: 25376160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.